25-Feb-2025 3:05 PM CST - Business Wire Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 45th Annual Health Care Conference: Exelixis is scheduled to present at 9:50 a.m. ET / 6:50 a.m. PT on Tuesday, March 4 in Boston. Barclays 27th Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:30 p.m. ET / 10:30 a.m. PT on Tuesday, March 11 in Miami. 2025 Leerink Partners Glo
13-Feb-2025 3:05 PM CST - Business Wire Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET / 11:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally am
11-Feb-2025 3:05 PM CST - Business Wire Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. Exelixis delivered a strong fourth quarter of 2024, positioning us well to maximize success in 2025, said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. Due to the continu
28-Jan-2025 3:05 PM CST - Business Wire Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 11, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the companys website. To access the conference call, please register using t
12-Jan-2025 3:00 PM CST - Business Wire Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 and delivered an update on its business. Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as well as multiple data readouts for zanzalintinib and across its diversified pipeline of small molecules and biotherapeutics w
6-Jan-2025 3:05 PM CST - Business Wire Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the companys President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location
27-Nov-2024 3:05 PM CST - Business Wire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City. Citi 2024 Global Healthcare Conference: Exelixis is scheduled to present at 1:45 p.m. ET / 10:45 a.m. PT on Wednesday, December 4 in Miami. To access the w
7-Nov-2024 3:05 PM CST - Business Wire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheims Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston. Stifel 2024 Healthcare Conference: Exelixis is scheduled to present at 10:20 a.m. ET / 7:20 a.m. PT on Monday, November 18 in New York City. Jefferies Lo
29-Oct-2024 3:05 PM CST - Business Wire Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones. The favorable ruling on our cabozantinib intellectual property estate and recently announced zanzalintinib development collaboration with Merck have generated important momentum to drive future grow
25-Feb-2025 3:05 PM CST - Business Wire Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 45th Annual Health Care Conference: Exelixis is scheduled to present at 9:50 a.m. ET / 6:50 a.m. PT on Tuesday, March 4 in Boston. Barclays 27th Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:30 p.m. ET / 10:30 a.m. PT on Tuesday, March 11 in Miami. 2025 Leerink Partners Glo
13-Feb-2025 3:05 PM CST - Business Wire Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET / 11:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally am
11-Feb-2025 3:05 PM CST - Business Wire Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. Exelixis delivered a strong fourth quarter of 2024, positioning us well to maximize success in 2025, said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. Due to the continu
28-Jan-2025 3:05 PM CST - Business Wire Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 11, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the companys website. To access the conference call, please register using t
12-Jan-2025 3:00 PM CST - Business Wire Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 and delivered an update on its business. Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as well as multiple data readouts for zanzalintinib and across its diversified pipeline of small molecules and biotherapeutics w
6-Jan-2025 3:05 PM CST - Business Wire Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the companys President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location
27-Nov-2024 3:05 PM CST - Business Wire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City. Citi 2024 Global Healthcare Conference: Exelixis is scheduled to present at 1:45 p.m. ET / 10:45 a.m. PT on Wednesday, December 4 in Miami. To access the w
7-Nov-2024 3:05 PM CST - Business Wire Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheims Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston. Stifel 2024 Healthcare Conference: Exelixis is scheduled to present at 10:20 a.m. ET / 7:20 a.m. PT on Monday, November 18 in New York City. Jefferies Lo
29-Oct-2024 3:05 PM CST - Business Wire Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones. The favorable ruling on our cabozantinib intellectual property estate and recently announced zanzalintinib development collaboration with Merck have generated important momentum to drive future grow
